Tarsus Pharmaceuticals Inc (TARS)
Healthcare
Biotechnology
61.30 $
+3.9%
vs. previous close
Closing price · As of: 3. Aug 2026
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Tarsus Pharmaceuticals Inc (TARS) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 07/13/2026 | Current report (8-K) | Tarsus Pharmaceuticals, Inc. (TARS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers | View report → |
| 07/08/2026 | Current report (8-K) | Tarsus Pharmaceuticals, Inc. (TARS): Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits | View report → |
Showing the 100 most recent filings of the selected type.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.